Circulating tumor cell burden as a component of staging in multiple myeloma

Rajshekhar Chakraborty, MD, Columbia University Irving Medical Center, New York City, NY, discusses the potential of circulating tumor cells (CTCs) as a biomarker to predict the outcomes of patients with multiple myeloma. Dr Chakraborty explains that two recent studies showed that a higher burden of CTCs at diagnosis was predictive of a worse progression-free survival (PFS). In addition, adding CTC burden to current staging systems clearly improved the discrimination of these systems. Nevertheless, it is still necessary to determine the most appropriate CTC cutoff. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

• #education
• #speaker_rajshekhar_chakraborty
• #institution_columbia_university_irving_medical_center
• #event_isa_2022
• #format_interview
• #subject_multiple_myeloma
• #field_disease_biology
• #ctcs
• #circulating_tumor_cells
• #cutff
• #risk_stratification
• #r_iss